Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 12.41% is 51% below its 5-year average of 25.20%, near the low end of its 5-year range (10.82%–63.96%).
As of the fiscal period ended Tuesday, June 30, 2026. 61.49% below its 12-month average of 32.23%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 12.41%.
DEBT TO ASSETS RATIO
12.41%
DEBT TO ASSETS RATIO AVG TTM
32.23%
DEBT TO ASSETS RATIO AVG 3Y
31.69%
DEBT TO ASSETS RATIO AVG 5Y
25.20%
DEBT TO ASSETS RATIO AVG 10Y
27.57%
DEBT TO ASSETS RATIO AVG 15Y
28.69%
DEBT TO ASSETS RATIO AVG 20Y
34.24%
CURRENT VS TTM AVG
-61.49%
CURRENT VS 3Y AVG
-60.83%
CURRENT VS 5Y AVG
-50.74%
CURRENT VS 10Y AVG
-54.97%
CURRENT VS 15Y AVG
-56.74%
CURRENT VS 20Y AVG
-63.75%
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+13691.78%
vs the sector median at left
Nektar Therapeutics
Market Cap
$1.14B
Debt to Assets Ratio
12.41%
TTM Avg
32.23%
3Y Avg
31.69%
5Y Avg
25.20%
Market Cap
$1.14B
Debt to Assets Ratio
0.39%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.13B
Debt to Assets Ratio
0.23%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.13B
Debt to Assets Ratio
0.04%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.11B
Debt to Assets Ratio
0.44%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.11B
Debt to Assets Ratio
0.64%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.18B
Debt to Assets Ratio
0.45%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.10B
Debt to Assets Ratio
0.08%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nektar Therapeutics (NKTR) | $1.14B | 12.41% | 32.23% | 31.69% | 25.20% |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.14B | 0.39% | N/A | N/A | N/A |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.13B | 0.23% | N/A | N/A | N/A |
| Harrow Health, Inc. (HROW)vs › | $1.13B | 0.72% | N/A | N/A | N/A |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.13B | 0.04% | N/A | N/A | N/A |
| Replimune Group, Inc. (REPL)vs › | $1.11B | 0.44% | N/A | N/A | N/A |
| Tandem Diabetes Care, Inc. (TNDM)vs › | $1.11B | 0.64% | N/A | N/A | N/A |
| MannKind Corporation (MNKD)vs › | $1.18B | 0.45% | N/A | N/A | N/A |
| STAAR Surgical Company (STAA)vs › | $1.10B | 0.08% | N/A | N/A | N/A |
| First Tracks Biotherapeutics Inc (TRAX)vs › | $1.10B | 0.02% | N/A | N/A | N/A |
Debt/Assets
12.4%
Debt/Equity
0.15
Current Ratio
10.42
Interest Coverage
-5.0x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 12.41% |
| 2026-03-31 | 18.79% |
| 2025-12-31 | 53.10% |
| 2025-09-30 | 30.50% |
| 2025-06-30 | 46.33% |
| 2025-03-31 | 39.16% |
| 2024-12-31 | 33.75% |
| 2024-09-30 | 35.15% |
| 2024-06-30 | 63.96% |
| 2024-03-31 | 28.81% |
| 2023-12-31 | 29.59% |
| 2023-09-30 | 27.43% |
| 2023-06-30 | 25.24% |
| 2023-03-31 | 22.82% |
| 2022-12-31 | 18.50% |
| 2022-09-30 | 17.24% |
| 2022-06-30 | 16.18% |
| 2022-03-31 | 13.89% |
| 2021-12-31 | 12.82% |
| 2021-09-30 | 11.47% |
| 2021-06-30 | 10.82% |
| 2021-03-31 | 10.32% |
| 2020-12-31 | 9.77% |
| 2020-09-30 | 10.23% |
| 2020-06-30 | 9.83% |
| 2020-03-31 | 21.83% |
| 2019-12-31 | 20.64% |
| 2019-09-30 | 19.28% |
| 2019-06-30 | 16.50% |
| 2019-03-31 | 15.88% |
| 2018-12-31 | 11.49% |
| 2018-09-30 | 10.96% |
| 2018-06-30 | 10.64% |
| 2018-03-31 | 49.45% |
| 2017-12-31 | 48.19% |
| 2017-09-30 | 42.48% |
| 2017-06-30 | 52.14% |
| 2017-03-31 | 47.01% |
| 2016-12-31 | 43.70% |
| 2016-09-30 | 58.23% |
| 2016-06-30 | 53.76% |
| 2016-03-31 | 50.87% |
| 2015-12-31 | 49.39% |
| 2015-09-30 | 29.43% |
| 2015-06-30 | 29.24% |
| 2015-03-31 | 27.00% |
| 2014-12-31 | 30.26% |
| 2014-09-30 | 27.33% |
| 2014-06-30 | 27.40% |
| 2014-03-31 | 27.11% |
| 2013-12-31 | 31.43% |
| 2013-09-30 | 34.99% |
| 2013-06-30 | 32.68% |
| 2013-03-31 | 30.31% |
| 2012-12-31 | 27.44% |
| 2012-09-30 | 25.38% |
| 2012-06-30 | 34.13% |
| 2012-03-31 | 32.94% |
| 2011-12-31 | 37.84% |
| 2011-09-30 | 35.52% |
| 2011-06-30 | 34.41% |
| 2011-03-31 | 32.85% |
| 2010-12-31 | 44.50% |
| 2010-09-30 | 46.24% |
| 2010-06-30 | 43.88% |
| 2010-03-31 | 42.53% |
| 2009-12-31 | 40.62% |
| 2009-09-30 | 51.74% |
| 2009-06-30 | 49.59% |
| 2009-03-31 | 46.44% |
| 2008-12-31 | 41.98% |
| 2008-09-30 | 59.31% |
| 2008-06-30 | 55.43% |
| 2008-03-31 | 52.59% |
| 2007-12-31 | 46.75% |
| 2007-09-30 | 54.82% |
| 2007-06-30 | 57.11% |
| 2007-03-31 | 56.31% |
| 2006-12-31 | 57.03% |
| 2006-09-30 | 55.45% |
| 2006-06-30 | 52.98% |
| 2006-03-31 | 52.08% |
| 2005-12-31 | 51.06% |
| 2005-09-30 | 46.31% |
| 2005-06-30 | 28.08% |
| 2005-03-31 | 27.49% |
| 2004-12-31 | 26.72% |
| 2004-09-30 | 26.90% |
| 2004-06-30 | 27.06% |
| 2004-03-31 | 27.25% |
| 2003-12-31 | 63.77% |
| 2003-09-30 | 67.15% |
| 2003-06-30 | 64.75% |
| 2003-03-31 | 58.82% |
| 2002-12-31 | 54.73% |
| 2002-09-30 | 53.06% |
